FibroGen, Inc. (0IL8.L)

USD 0.29

(8.4%)

Revenue Summary of FibroGen, Inc.

  • FibroGen, Inc.'s latest annual revenue in 2023 was 147.75 Million USD , up 4.99% from previous year.
  • FibroGen, Inc.'s latest quarterly revenue in 2024 Q2 was 50.64 Million USD , down -9.41% from previous quarter.
  • FibroGen, Inc. reported a annual revenue of 140.73 Million USD in annual revenue 2022, down -40.19% from previous year.
  • FibroGen, Inc. reported a annual revenue of 235.3 Million USD in annual revenue 2021, up 33.46% from previous year.
  • FibroGen, Inc. reported a quarterly revenue of 55.9 Million USD for 2024 Q1, up 105.99% from previous quarter.
  • FibroGen, Inc. reported a quarterly revenue of 40.13 Million USD for 2023 Q3, down -9.44% from previous quarter.

Annual Revenue Chart of FibroGen, Inc. (2023 - 2012)

Historical Annual Revenue of FibroGen, Inc. (2023 - 2012)

Year Revenue Revenue Growth
2023 147.75 Million USD 4.99%
2022 140.73 Million USD -40.19%
2021 235.3 Million USD 33.46%
2020 176.31 Million USD -31.28%
2019 256.57 Million USD 20.48%
2018 212.95 Million USD 69.46%
2017 125.66 Million USD -30.02%
2016 179.57 Million USD -0.69%
2015 180.82 Million USD 31.41%
2014 137.6 Million USD 34.68%
2013 102.17 Million USD 54.96%
2012 65.93 Million USD 0.0%

Peer Revenue Comparison of FibroGen, Inc.

Name Revenue Revenue Difference
Thermo Fisher Scientific Inc. 42.85 Billion USD 99.655%
Dynavax Technologies Corporation 232.28 Million USD 36.392%
Illumina, Inc. 4.5 Billion USD 96.72%
IQVIA Holdings Inc. 14.98 Billion USD 99.014%
Biogen Inc. 9.83 Billion USD 98.498%
Iovance Biotherapeutics, Inc. 1.18 Million USD -12326.577%
Mettler-Toledo International Inc. 3.78 Billion USD 96.1%
Sarepta Therapeutics, Inc. 1.24 Billion USD 88.116%
Supernus Pharmaceuticals, Inc. 607.52 Million USD 75.68%
Waters Corporation 2.95 Billion USD 95.002%
Perrigo Company plc 4.65 Billion USD 96.826%
uniQure N.V. 15.84 Million USD -832.601%
Agios Pharmaceuticals, Inc. 26.82 Million USD -450.841%
Amicus Therapeutics, Inc. 399.35 Million USD 63.002%
Atara Biotherapeutics, Inc. 8.57 Million USD -1623.457%
bluebird bio, Inc. 29.49 Million USD -400.905%
Cara Therapeutics, Inc. 20.96 Million USD -604.655%
Imunon, Inc. - USD -Infinity%
Myriad Genetics, Inc. 678.4 Million USD 78.221%
Neurocrine Biosciences, Inc. 1.88 Billion USD 92.17%
Nektar Therapeutics 90.12 Million USD -63.947%
Editas Medicine, Inc. 78.12 Million USD -89.127%
Verastem, Inc. - USD -Infinity%
Walgreens Boots Alliance, Inc. 147.65 Billion USD 99.9%
Corbus Pharmaceuticals Holdings, Inc. - USD -Infinity%
Heron Therapeutics, Inc. 127.04 Million USD -16.3%
Unity Biotechnology, Inc. - USD -Infinity%
BioMarin Pharmaceutical Inc. 2.41 Billion USD 93.893%
Sangamo Therapeutics, Inc. 176.23 Million USD 16.161%
Evolus, Inc. 202.08 Million USD 26.886%
Adicet Bio, Inc. - USD -Infinity%
Aclaris Therapeutics, Inc. 31.24 Million USD -372.822%
Regeneron Pharmaceuticals, Inc. 13.11 Billion USD 98.874%
Esperion Therapeutics, Inc. 116.33 Million USD -27.007%
Agilent Technologies, Inc. 6.83 Billion USD 97.838%
OPKO Health, Inc. 863.49 Million USD 82.889%
Homology Medicines, Inc. -6.65 Million USD 2321.501%
Geron Corporation 237 Thousand USD -62242.616%
Alnylam Pharmaceuticals, Inc. 1.82 Billion USD 91.919%
Exelixis, Inc. 1.83 Billion USD 91.927%
Viking Therapeutics, Inc. - USD -Infinity%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. 36.27 Million USD -307.311%
Zoetis Inc. 8.54 Billion USD 98.271%
Axsome Therapeutics, Inc. 270.6 Million USD 45.398%
Abeona Therapeutics Inc. 3.5 Million USD -4121.486%
Vertex Pharmaceuticals Incorporated 9.86 Billion USD 98.503%
Kala Pharmaceuticals, Inc. - USD -Infinity%
Ionis Pharmaceuticals, Inc. 787.64 Million USD 81.241%
Corcept Therapeutics Incorporated 482.37 Million USD 69.37%
Halozyme Therapeutics, Inc. 829.25 Million USD 82.183%
Blueprint Medicines Corporation 249.38 Million USD 40.752%
Insmed Incorporated 305.2 Million USD 51.59%
TG Therapeutics, Inc. 233.66 Million USD 36.767%
Incyte Corporation 3.69 Billion USD 96.002%
Emergent BioSolutions Inc. 1.04 Billion USD 85.919%